Table 2. Levels of the two major endocannabinoids (2-AG and AEA) in brain regions relevant for social and cognitive behavior (amygdala and hippocampus) after 10 days treatment with VEH or JZL184.
(WT VEH, n = 6; WT JZL184, n = 6; CD VEH, n = 7; CD JZL184, n = 7). Statistical significance was calculated by Newman–Keuls post hoc test following two-way analysis of variance (ANOVA). ###p < 0.001 (treatment effect). Data are expressed as mean ± standard error of the mean (SEM).
| Amygdala | ||||
|---|---|---|---|---|
| WT VEH | WT JZL184 | CD VEH | CD JZL184 | |
| 2-AG (nmol/g) |
18.72 ± 4.60 | 122.96 ± 21.99### | 16.99 ± 0.86 | 128.33 ± 18.12### |
| AEA(pmol/g) | 6.89 ± 1.04 | 5.34 ± 0.53 | 6.64 ± 0.41 | 4.69 ± 0.41 |
| Hippocampus | ||||
| WT VEH | WT JZL184 | CD VEH | CD JZL184 | |
| 2-AG (nmol/g) |
9.11 ± 1.45 | 75.55 ± 14.95### | 9.01 ± 0.46 | 86.46 ± 15.25### |
| AEA (pmol/g) |
8.30 ± 0.77 | 8.26 ± 0.57 | 8.80 ± 0.63 | 7.85 ± 0.87 |